The Life Sciences team advised Cathay Health, Polaris Partners, and Newpath Partners on leading Kojin Therapeutics’ Series A financing. The round also included participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
Cathay Health is the healthcare and life sciences focused venture capital arm of global investment firm Cathay Capital.
Polaris invests in healthcare and technology companies across all stages from founding to profitable growth.
Newpath is a founder-focused life sciences venture capital firm.
Kojin is a leading company developing new targeted therapeutics based on cell state and ferroptosis biology. Ferroptosis is a type of programmed cell death dependent on iron and related to the accumulation of lipid peroxides, and is distinct from more common forms of regulated cell death like apoptosis.
The funding will be used to accelerate Kojin’s drug discovery platform based on its groundbreaking approach to cell state and ferroptosis biology and advance a pipeline of therapeutics, with an initial focus on oncology.
The Goodwin team was led by Kris Brown, Mayan Katz and Jamila Hollins (Corporate) and included Cathy McCarty (IP); Jacob Osborn and Justin Pierce (Global Trade); Ettore Santucci (Opinions); and Wenlan Geng.
For more details, read the press release and articles in Fierce Biotech and Boston Business Journal.